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ABSTRACT 
 
Background  
Mast cells are tissue-resident cells of the innate immunity implicated in the 
pathogenesis of many autoimmune diseases, including rheumatoid arthritis 
(RA). In fact, they are present in synovia and their activation has been 
linked to the inflammatory responses driving the development of RA. 
However, their exact contribution to the development of RA is still unclear. 
In particular, their interactions with other immune cells at synovial levels 
and their correlation to disease outcomes have never been investigated in a 
systematic fashion.  
Objective  
Aim of this PhD project was to elucidate the role of mast cells in 
rheumatoid arthritis, by studying their cellular interaction at synovial levels, 
their influence on the activation of immune cells and, finally, their 
correlation with disease outcomes.  
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Results  
In the synovia of RA patients, mast cells correlated with the degree of local 
inflammations and cellular infiltration. In particular, higher numbers of 
mast cells were associated with the presence of lymphoid aggregates, and 
mast cells were localized in close proximity of cellular aggregates of B and 
T cells. In vitro, mast cells were able to modulate the responses of immune 
cells, suppressing the pro-inflammatory activation of monocytes and 
supporting B cells survival, differentiation and antibody production. In 
patients with early RA, high numbers of synovial mast cells were 
associated with antibody positive disease and with systemic inflammatory 
markers. At the 12 months follow-up, baseline mast cells represented an 
independent predictor of radiographic progression.  
Conclusions  
Mast cells, as part of the inflammatory infiltrate in the synovia of RA 
patients, are able to induce both pro- and anti-inflammatory immune 
responses, which might explain the conflicting results obtained so far with 
experimental models not taking into account their tunable 
immunomodulatory properties. The ex vivo analysis performed in the 
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synovia of early RA patients indicate that mast cell presence can be used to 
further dissect the disease heterogeneity, as mast cells clustered with 
antibody positivity and with a higher degree of local and system 
inflammation. Interestingly, independently from these associations, mast 
cell presence at baseline represented a predictor of radiographic progression 
at 1 year. Overall, our data suggest that mast cells play a multifaceted role 
in the pathogenesis of RA, warranting additional investigations to further 
assess their involvement in disease development, progression and response 
to therapy.  
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INTRODUCTION 
 
Mast cells as effector cells of innate and adaptive immunity 
Mast cells (MCs) are granulated tissue-resident cells of hematopoietic 
lineage 1. Deriving from specific hematopoietic precursors, they circulate as 
immature cells and migrate into vascularized tissues, where they complete 
their differentiation and reside in the proximity of blood vessels. As they 
are present in all anatomic sites exposed to the external environment, they 
represent, together with dendritic cells, the first cells of the immune system 
to interact with environmental antigens, pathogens and toxins. Therefore, 
they can be considered “sentinels” of the immune system 2, localized on the 
frontline, and ready to fight in response to infections and other stimuli. In 
fact, mast cells express many receptors (i.e. complement receptors, Fc, and 
Toll-like receptors), and are able to sense danger signals and react by 
quickly releasing a wide range of mediators, both pre-formed ( e.g. 
histamine, etc) and newly produced (cytokines and chemokines). 
Even though these innate immunity functions partially overlap with other 
immune cells (e.g. neutrophils, macrophages, dendritic cells), evidences 
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from animal models demonstrated that the absence of mast cells 
significantly impairs the ability to respond to bacterial infections 3,4. 
In line with their importance in the fight against pathogens, it is also worth 
noticing that mast cells are highly conserved throughout evolution 5, as 
MC-like cells, containing histamine and heparin, have been described in 
very simple invertebrates 6. In higher species, with the evolution of adaptive 
immunity, mast cells acquire the expression of the high affinity receptors 
for IgE (FceRI) 7. Triggering of the IgE bound to the FceRI induces mast 
cells to degranulate, with the quick release of pre-formed mediators. 
Because of this property, together with circulating basophils, mast cells are 
mainly known as effector cells of IgE-mediated (Th2) responses, an arm of 
the adaptive immune system develop to fight multicellular pathogens, such 
as helminths 8, and in recent years recognized as the mechanism at the basis 
of hypersensitivity reactions 9. 
 
Mast cells and the modulation of adaptive immune responses 
In addition to their functions as effector cells, recent evidences suggest that 
mast cells are able to modulate the adaptive immunity, therefore 
representing an important link between innate and adaptive immunity 10. 
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For example, mast cells express MHC class II and have been shown to 
induce antigen-specific T cell activation 11-13. Vice versa, mediators derived 
from cells of the adaptive immunity can influence mast cell activation, as 
shown for example by the ability of IgG to activate mast cells through the 
FcgammaR 14,15. In the crosstalk between mast cells and adaptive immunity, 
the protective role of mast cells in the response against pathogens, i.e. their 
ability to orchestrate Type 2 responses against helminths 11,16, can become 
harmful when the immune response is dysregulated, and mast cells can 
potentially contribute to the deleterious responses leading to allergy and 
autoimmunity 5. 
A great deal of evidences indicate that mast cells have deleterious effects in 
these contexts, given their ability to release mediators with clear pro-
inflammatory effects, such as histamine, and several prostaglandins and 
cytokines.  
Albeit mostly known for their pro-inflammatory effects, many of these 
mediators have been also shown to have opposite effects.  
As an example, histamine is well-known for its pro-inflammatory functions 
(e.g. vasodilation, increased vascular permeability, bronchospasm etc). 
However, we have shown that basophil-derived histamine is able to shown 
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to suppress the pro-inflammatory activation of monocytes 17, thereby 
contributing to the down-regulation of immune responses. 
Although apparently contra intuitive, it is not surprising that the same cells, 
mechanisms and mediators responsible for the early inflammatory 
responses (e.g. histamine-induced vasodilation) are also able to suppress 
inflammation (e.g. the above cited histamine-induced immune modulation). 
In fact, resolution is a process starting early in the course of inflammation 
in order to restore homeostasis, prevent tissue damage and facilitate wound 
repair.  
In line with this concept, mast cell have been shown to produce mediators 
known for their immune regulatory effects toward the resolution of 
inflammation 18, such as IL-10, and mast cell-derived IL-10 has been shown 
to have protective effects in vivo 19-21. 
Overall, mast cells should be considered more than effector cells, as they 
are able to orchestrate the adaptive immune responses, acting as 
immunomodulatory/ regulatory cells that can be finely tuned by multiple 
stimuli 22,23. 
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Mast cells in rheumatoid arthritis  
As immune cells present the synovial membrane, mast cells have been 
implicated in the pathogenesis of many rheumatic diseases, including 
Rheumatoid Arthritis (RA) 24. The synovial membrane is the primary 
inflammatory site of RA and its inflammation – i.e. synovitis - is mainly 
characterised by thickening of the synovial layer, with cellular hyperplasia 
and infiltration of immune cells 25. Mast cells are among the immune cells 
found in the inflamed synovia of RA patients. They are known to be present 
as resident cells in healthy synovia 26, and an increase in their numbers has 
been shown to accompany the cellular hyperplasia in RA 27-29. Starting from 
this observation, many attempts have been made to further elucidate their 
involvement in the disease process leading to RA. Robust laboratory 
evidences support the hypothesis of a pro-inflammatory (pro-arthritogenic) 
role of mast cells in the pathogenesis of RA, and the pathways leading to 
mast cell activation in the context of rheumatic diseases and their effector 
functions have recently been extensively reviewed 30. However, mast cell 
activation in inflamed tissues is sometimes considered as a mere 
consequence of tissue inflammation, rather than playing a specific role in 
disease pathogenesis. The functional contribution of mast cells to RA and 
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other autoimmune diseases is difficult to assess in patients, because of the 
lack of specific mast cell inhibitors for clinical studies. Therefore, the study 
of their functional relevance relies on the use of animal models, that in most 
cases do not fully reproduce the human disease, only representing one 
component of the immune response 31. Therefore, it is not surprising that 
different animal models generated inconclusive results, failing to confirm 
specific role for mast cells, so that many of their functions have been 
labelled as redundant. More recently, the inconsistency of the results in 
vivo has been attributed to the experimental flaws of the techniques to 
obtain mast cell depletion 32. In fact, early experiments used models of mast 
cell depletion based on mutations affecting c- kit (Stem Cell Factor 
receptor) structure or expression and that consequently exhibit a profound 
MC deficiency together with a variety of other phenotypic abnormalities. 
The promising results obtained in such models have been subsequently 
challenged by using new ‘KIT-independent’ models of MC deficiency, so 
that, in many contexts, the involvement of mast cells have been now 
labelled as redundant 33.  
A recent publication further addressed the complexity of the animal models 
to study the involvement of mast cells in RA, finally shedding some light 
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on the inconsistent results obtained so far 34. Schubert and colleagues 
studied MC functions using both antibody-induced and antigen-induced 
experimental arthritis in Mcpt5-Cre;iDTR mice as a model of inducible 
MC-deficiency that is independent of Kit mutations and reflects a normal 
immune system despite the absence of MCs. Consistently with previous 
findings 35 MC role was found to be redundant in the K/BxN serum-induced 
joint inflammation. However, in this model, joint inflammation is induced 
passively by the injection of an arthritogenic serum, therefore only 
assessing the effector functions of the immune system. This is suggesting 
that mast cells are dispensable for this type of response, which is only a part 
of the complex immune response leading to the development of RA. On the 
contrary, mast cell depletion significantly reduced the disease severity in a 
model of collagen-induced arthritis, based on an active immunization with 
an antigen (collagen), more accurately mimicking the early phases of RA, 
in which mast cells could contribute to the breach of tolerance against self-
antigens. The conclusion from this study is that mast cells could play a role 
in the early immune response in the course of arthritis, while their functions 
seem to be redundant in the later effector phases.  
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Albeit fascinating, the transfer of these results to human disease is complex, 
especially because animal models rely on genetically identical mouse 
strains, clearly not taking into account the heterogeneity of the human 
diseases, which is particularly true for RA, well recognized as a highly 
heterogeneous disease, with enormous differences between patients in 
terms of pathogenesis 36, disease progression and response to therapy25,37. In 
this context, the previously discussed evidences of the anti-inflammatory 
and immunomodulatory roles of mast cells could offer an alternative 
explanation for the conflicting results obtained in different animal models. 
In particular, it is intriguing to speculate that mast cells, as tunable effector 
cells, have various functions in different patient subsets, and, possibly, in 
different disease stages, adding more complexity to the heterogeneity of 
RA.  
The only way to confirm this hypothesis would be to study the presence of 
mast cell directly at synovial level, which has been challenging in the past, 
with a few studies relying on synovial tissue obtained by arthroscopy or 
during surgery in patients with long-standing disease 38,39. However, the 
recent technological advancements of ultrasound-guided synovial biopsies 
allowed to obtain synovial tissue from patients with a minimally invasive 
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procedure 40. Therefore, synovial histology has been proposed as a tool to 
dissect the heterogeneity of RA, and the study of synovial histopathology in 
early patients has led the stratification of patients in subgroups, according 
to histological patterns (pathotypes), that are emerging as potential 
taxonomic classifiers of disease phenotypes 41. In particular, synovial 
histopathology, depending on predominant type of infiltrating cells, has 
been defined as fibroid, myeloid and lymphoid. The latter is characterized 
as lymphoid follicle-like structures ranging from T and B cell aggregates to 
highly organized structures comprising follicular DC (fDC) networks 
reminiscent of germinal centres (GCs). These structures are present in up to 
40% of RA patients 41,42 and have been associated with severe disease, T 
cell priming, and autoantibody production 43-45. Particularly interesting is 
the evidence that these ectopic lymphoid structures (ELS) support the local 
ongoing production of class-switched autoantibodies 45, including anti-
citrullinated protein/peptide antibodies (ACPA), which are highly specific 
markers of RA, predict a poor prognosis, and have been suggested to be 
pathogenic. 
Although mast cell presence in synovia has been known for a long time, it 
is not clear if their presence is associated with any of the pathotypes and, 
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ultimately, if the analysis of synovial mast cells could contribute to a better 
definition of the synovial histopathology. 
Aim of this PhD project was to elucidate the role of mast cells in 
rheumatoid arthritis, by studying their cellular interaction at synovial levels, 
their influence on the activation of immune cells and, finally, their 
correlation with disease outcomes. 
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MATHERIALS AND METHODS 
 
Peripheral blood derived mast cells. 
Buffy coat cells were obtained from the peripheral blood of healthy 
volunteers, with samples collected from a blood bank. CD34+ 
hematopoietic stem cells were isolated from peripheral blood mononuclear 
cells (PBMCs) using CD34 microbeads (Miltenyi Biotec). Isolated CD34+ 
stem cells were differentiated into mast cells using a previously described 
method 46. After 6–8 weeks, the purity of the mast cells was determined by 
flow cytometry analyses for the expression of CD117 (c-Kit), Ig E-class–
binding Fc receptor type I (FcERI), and CD203c; purity ranged from 90% 
to 99%. 
Mast cell activation 
Plate bound IgG were used as a model to study Fc-receptor-mediated-
activation of mast cells 47,48. Briefly, culture plates (flat-bottom 96-wells or 
48-wells) were coated with 100 g/mL of purified human IgG (Jackson 
Immunoresearch) in PBS for 1,5 hours at 37 °C and washed 2x with PBS 
Mast cells were cultured at a concentration of 1x106/mL in RPMI-1640 
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medium containing 10% fetal calf serum (FCS), glutamine, penicillin, 
streptomycin (Invitrogen) + 100 ng/mL of SCF (Tebu-bio), without or with 
100 ng/mL of recombinant human IL-33 (PeproTech). After 24h, cells were 
harvested, supernatants collected and stored at -20°C and cells used for 
flow cytometry analyses. 
 
IgG-ACPA mediated mast cell activation 
CCP2 peptides were obtained from Dr. Drijfhout, Department of IHB, 
LUMC, The Netherlands. Nunc Maxisorp plates (VWR) were coated with 
CCP2 peptide or arginine control peptide and incubated at 37 degrees for 1 
hour with serum of ACPA-positive RA patients, diluted 50x in 
PBS/0,1%BSA. After washing, mast cells were added to the wells, and 
cultured in the presence or absence of 100 ng/mL of recombinant human 
IL-33. After 24h, cells were harvested, supernatants collected and stored at 
-20°C. 
 
Monocyte isolation and stimulation with Mast cell supernatants 
CD14+ monocytes were isolated from buffy coats PBMCs using magnetic-
labeled anti-CD14 beads (Miltenyi Biotec), according to the manufacturer’s 
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instructions. Isolated monocytes (purity > 95%) were cultured in the same 
medium used for mast cells. 
Monocytes were incubated with mast cell supernatants (diluted 1:4 in 
medium) or control media and stimulated with lipopolysaccharides (LPS) 
from Salmonella typhosa (Sigma-Aldrich) at a concentration of 5 ng/mL. 
After overnight (18h) incubation, cells were harvested, supernatants 
collected and stored at -20°C for further analysis. Cells were used for flow 
cytometry analyses. For blocking experiments, supernatants of activated 
mast cells were pre-incubated with anti-IL-10 antibody or matching isotype 
control Rat IgG2a (BDBiosciences) at 10 g/ for 30 min at 37°C in 5% 
CO2 atmosphere, prior to addition to the monocytes. For inhibition of 
histamine, monocytes were pre-incubated for 30 min at 37°C with 
histamine receptor 2 antagonist ranitidine at 10-4 M (Sigma) 17.  
B-cell isolation  
Human B cells were immunomagnetically selected from tonsils obtained 
following routine tonsillectomy. Briefly, tonsils were washed with chilled 
(4°C) MACS buffer (phosphate buffered saline (PBS), 0.5% FCS and 2 
mM EDTA), minced and gently mashed through a cell strainer. Cells were 
washed, centrifuged and B cells were isolated using anti-IgD microbeads 
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(Miltenyi Biotec), according to the manufacturer’s instructions. The purity 
of IgD+ unswitched B cell isolation was checked by fluorescence activated 
cell sorting.  
Co-culture of B cells and Mast cells  
IgD+ B cells and mast cells were resuspended at a concentration of 
1x106/mL in IMDM-1640 medium containing 10% fetal calf serum (FCS), 
glutamine, penicillin, streptomycin (Invitrogen). In cell–cell contact 
experiments, B cells (1×10 6 cells/300 µl/ well) were cultured together with 
mast cells at a ratio of 1:6 (1x10/ 50 µl/ well) In transwell experiments, 
microporous PET cell inserts (3 µm pore) were employed, with mast cells 
in the upper well and B cells on the base of the well. B cells were activated 
with 1ug/mL of CPG. After 6 days, cells were harvested, supernatants 
collected and stored at -20°C for further analysis and cells were 
resuspended for FACS analysis. In parallel experiments, B cells were 
labelled with CFSE (Biolegend) a 5 µM, according to the manufacturer’s 
protocol.  
Patient samples 
Serum samples were obtained from RA patients, with the presence of total 
IgG-ACPA tested by routine diagnostic ELISA. Synovial tissue for 
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immunofluorescence analysis was obtained from 3 patients (aged 59, 70 
and 76) with ACPA+ established RA patients who had undergone surgery. 
For mRNA sequencing, mRNA was extracted from the synovial tissues 
obtained from ultrasound guided biopsies of patients with early (< 12 
months) active RA naïve for DMARDs therapy (n=40), enrolled in the 
Pathobiology of Early Arthritis Cohort (PEAC) cohort 
http://http://www.peac-mrc.mds.qmul.ac.uk 41 of the Centre for 
Experimental Medicine and Rheumatology of Queen Mary University 
(London). Additionally, the presence of mast cells was analysed by 
immunohistochemistry in a total of 90 patients from the PEAC cohort. The 
PEAC is a prospective, observational study in patients with early 
symptomatic arthritis (3-12months durations), in which patients were 
categorized, monitored and treated according to best practice. X rays at 0 
and 12 months were scored according to the Van der Heijde-modified 
Sharp method 49 and radiographic progression was defined as an increase in 
the Van der Heijde-modified Sharp score by more than 1 points over 1 year. 
All patients selected for our analyses fulfilled the 1987 revised American 
College of Rheumatology criteria for RA 50. Written informed consent was 
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obtained from the patients, and the study was approved by local human 
ethics committees. 
Immunofluorescence  
Samples were fixed by 4% (wt/vol) formaldehyde (Merck) in PBS and 
stored in 70% (vol/vol) ethanol. Tissues were embedded in paraffin, 
sectioned at 4 μm. Slides were deparaffinised with xylene (Merck), 
endogenous peroxidase activity was blocked with 1% hydrogen peroxide 
(Merck) in methanol for 10 min. After antigen retrieval with a Tris/EDTA 
solution (pH9; DAKO) for 30 min at 96 °C, slides were stained with 
primary antibodies (tryptase, CD117, CD14, CD3, CD20) or corresponding 
isotypes (Dako). Detection was performed using the appropriate secondary 
antibodies (Invitrogen). All slides were mounted with Vectashield Hard Set 
mounting medium with DAPI (Vector Laboratories). Slides were stored in 
the dark at 4ºC before visualisation using a Zeiss Axio Scope A1 and 
AxioVision 4.9.1 or a microscope name and cellSens software (Olympus).  
 
Immunohistochemistry analysis of synovial tissue 
Sections of paraffin embedded synovial tissue obtained by ultrasound-
guided synovial biopsy from DMARD-naïve patients with early (<12 
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months) RA (n=90) were stained with H&E and underwent semi-
quantitative (SQ) scoring (0-9) to determine the degree of synovitis, 
according to a previously validated method 51. Sequentially cut sections 
were stained by IHC for CD117+ MCs and immune cells (CD20+ B cells, 
CD3+ T cells, CD68+ macrophages and CD138+ plasma cells). Upon SQ 
scoring (0-4), sections were stratified into synovial pathotypes according to 
the degree of immune cell infiltration: (i) Lymphoid- grade 2/3 B cell 
aggregates, CD20≥ 2 and/or CD138>2 ii) Myeloid- CD68 SL≥ 2, CD20≤1 
and/or CD3≥1, CD138≤2 and iii) Fibroid- CD68 SL<2 and CD3, CD20, 
CD138<1).  
 
Flow cytometry 
For flow cytometry staining, cells were incubated with fluorochrome-
conjugated antibodies diluted in PBS 0.5% BSA at 4 ºC for 30 min. To 
exclude dead cells, just prior to flow cytometric acquisition, 0.2 uM DAPI 
(Invitrogen) was added. Flow cytometric acquisition was performed on 
LSR-II (BD). Analysis was performed using FACS Diva (BD) and FlowJo 
software (Tree Star Inc.).  
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Measurement of cytokines and immunoglobulins 
Quantitative immunoassays in mast cell culture supernatants were 
performed using the 42-plex cytokine Milliplex assay (Millipore). 
Additionally, the following ELISA kits were used: Human IL-8 ELISA 
Ready-SET-Go!® (ebioscience), Human TNF ELISA set (BD Biosciences), 
IL-10 Human PeliPair™ ELISA kit (Sanquin Reagents) and Histamine 
ELISA kit (Neogen), IgG and IgM ELISA kit (Jackson Immunoresearch). 
mRNA sequencing  
Total RNA from synovial tissue was extracted using the Qiagen RNeasy 
mini kit as per manufacturer’s protocol including the on-column DNase 
digestion. Quality control of samples was done to determine RNA quantity 
and quality prior to their processing by RNA-seq. The concentration of total 
RNA samples was determined using NanoDrop 8000 (Thermo Scientific). 
The integrity of RNA samples 1was determined using both 2100 
Bioanalyzer and 2200 TapeStation (Agilent Technologies). Where 
available, 1ug of total RNA was used as an input material for library 
preparation using TruSeq RNA Sample Preparation Kit v2 (Illumina). 
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Generated libraries were amplified with 10 cycles of PCR. Size of the 
libraries was confirmed using 2200 TapeStation and High Sensitivity D1K 
screen tape (Agilent Technologies) and their concentration was determined 
by qPCR based method using Library quantification kit (KAPA). The 
libraries were first multiplexed (five per lane) and then sequenced on 
Illumina HiSeq2500 (Illumina) to generate 50 million of paired end 75 base 
pair reads (synovial samples). For the data analysis, the Genomic Short-
read Nucleotide Alignment Program (GSNAP) (http://research-
pub.gene.com/gmap/) was used to map and assemble transcripts using the 
UCSC hg19 human genome reference sequence and associated 
transcriptome map. 
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RESULTS 
 
Mast cells activation in rheumatoid arthritis  
We investigated the activation of mast cells by stimuli known to be present 
in human synovium and implicated in the pathogenesis of RA, such as IgG 
immune complexes, specifically ACPA-IgG. 
Mast cell activation, evaluated by measurement of CXCL8/IL-8 levels, was 
observed upon triggering with IgG ACPA immune complexes, which were 
formed by binding of the serum of patients with ACPA-positive RA to 
citrullinated peptides (Figure 1, A-B). Importantly, mast cells were not 
activated by ACPA-positive serum incubated with the arginine control or 
by serum from ACPA- negative patients. The activation of mast cells by 
IgG was significantly enhanced by TLR agonists 14, including endogenous 
ligands (e.g. HSP70), known to be present in synovia (Figure 1, C-D).  
Overall, these data indicate that mast cells can contribute to synovial 
inflammation by producing pro-inflammatory mediators (IL-8, a potent 
chemoattractant for neutrophils) upon triggering with IgG immune 
complexes, including ACPA immune complexes and that other stimuli 
present in synovia (e.g. TLR ligands) can further enhance this response. 
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This is in line with previous reports indicating a deleterious role for mast 
cells in RA 52,53 54, recently reviewed in 30. 
Figure 1. Activation of mast cells by ACPA immune complexes 
A, B Mast cells were stimulated on CCP-coated plates incubated with no serum (ctr) or 
serum of antibodies against citrullinated proteins (ACPA+) and ACPA− rheumatoid 
arthritis patients, as indicated, for 24 h, after which IL-8 production was measured in 
supernatant. Results are shown as the summary of all experiments (A) or pairwise (B), 
with each symbol representing an individual patient serum tested. C, IL-8 production by 
mast cells in response to combined triggering using plate-bound ACPA and HSP70 or 
their separate stimulations. Results are shown as the summary of all independent (n=5) 
experiments. D, IL-8 production after combined stimulation with HSP70 and ACPA 
(closed symbols) compared to the sum of IL-8 following separate stimulation with 
HSP70 and ACPA(open symbols). Asterisks indicate significant (p<0.05) differences 
between the indicated conditions, using paired samples t test.  
Modified from Suurmond J, Rivellese F, et al. Ann Rheum Dis. 2015 Oct;74(10):1915-
23.doi: 10.1136/annrheumdis-2014-205562 
33 
 
Mast cells as immunomodulatory cells in rheumatoid arthritis 
Having found that mast cells can be activated by IgG immune complexes, 
we assessed the influence of IL-33 on IgG-induced mast cell activation. 
Interestingly, IL-33 was shown to prime mast cells toward a Th2 & 
immunomodulatory phenotype. In fact, stimulation of mast cells with IL-33 
induced higher amounts of histamine and IL-10, compared to the induction 
CXCL8/IL-8 upon triggering with IgG (Figure 2, A). Likewise, only IL-33, 
and not pbIgG, induced the upregulation of the mast cell activation marker 
CD203c (Figure 2, B). The histamine release observed upon IL-33 
triggering was not accompanied by the upregulation of CD63, a marker of 
mast cell degranulation. Combination of the two stimuli led to an increased 
activation of mast cells, with the release of significantly higher amounts of 
CXCL8/IL-8, histamine and IL-10, as compared to unstimulated mast cells 
or to single stimuli (Fig 2 A, last columns). To discriminate between an 
additive or synergistic effect, we compared the sum of single stimuli with 
the actual amounts produced upon combined stimulation with IL-33 and 
pbIgG (Figure 2C, empty Vs filled dots). This comparison showed higher 
amounts of histamine and IL-10 with combined stimulation, indicating a 
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clear synergistic effect for these IL-33-triggered mediators, while for 
CXCL8/IL-8 only an additive effect was observed.  
Figure 2. Activation of mast cells via interleukin-33 (IL-33) and immune complexes 
Mast cells were triggered with IL-33 or plate bound IgG for 24h. A, CXCL8/IL-8, 
histamine and IL-10 measured by ELISA. Mean + SEM from 4 independent 
experiments (n=4). B, Expression of CD203c left, as Median Fluorescence Intensity 
(MFI) ratio to isotype, and CD63 (right), as % of positive mast cells. Each symbol 
represent a mast cells donor (n=12) from 5 independent experiments *p<0.05 
determined by ANOVA with Bonferroni’s post-test (for multiple comparisons) C, 
Synergy was assessed by comparing sums of mediators measured in single stimulations 
(IL-33 + IgG) and the actual values measured in the supernatants of cells simultaneously 
stimulated (IL-33 & IgG). Each symbol represents a mast cells donor (n=4) from 4 
independent experiments C, CXCL8/IL-8 levels, measured by ELISA, after incubation 
of mast cells with ACPA+ RA sera bound to citrullinated peptides or arginine controls 
(n=6 mast cell donors, with sera from 3 ACPA+ patients). D, Histogram (representative 
of 4 independent experiments, n= 4 mast cell donors) showing FcRIIa expression by 
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mast cells upon stimulation with IL-33 (black line) and blocking of IL-33 receptor ST2 
(dashed black line). On the right, expression of FcRs by mast cells without and with IL-
33 triggering, as MFI ratio to isotype. Each symbol represent a mast cells donor (n>7) 
from 5 independent experiments. *p<0.05 determined by ANOVA with Bonferroni’s 
post-test (for multiple comparisons) and by Student t test (for comparisons between two 
groups). Modified from Rivellese F, et al. Arthritis Rheumatol. 2015 Sep;67(9):2343-53. 
doi: 10.1002/art.39192. 
 
 
We next sought to identify the mechanism by which IL-33 enhances mast 
cell activation and hypothesized that IL-33 modulates the expression of Fc 
receptors on mast cells. Indeed, IL-33 induced a significant up regulation of 
the activating FcRIIa (Figure 2 D). This effect was mediated by the IL-33 
receptor ST2, as it could be blocked by anti-ST2 antibodies (Figure 2 D). 
Importantly, we did not detect expression of other FcRs by cultured human 
mast cells and these were not influenced by IL33 stimulation (Figure 2 D, 
right).  
Together, these results indicate that IL-33, via its receptor ST2, induces the 
up regulation of FcRIIa, enhancing the activation of mast cells upon 
triggering with pbIgG, as well as ACPA-IgG, as demonstrated by the 
increased production of CXCL8/IL-8. More specifically, IL-33 induces 
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IgG-triggered mast cells to release histamine and IL-10, but not CXCL8/IL-
8, in a synergistic fashion. To further support the notion that IL-33 is able to 
modulate mast cell activation by IgG, we performed a multiplex assay on 
MC supernatants.  
In line with previous literature, MCs triggered with IL-33 and pbIgG 
secreted a wide range of mediators 55-57. When comparing the two 
stimulations, we found that pbIgG induced higher amounts of classical pro-
inflammatory mediators, while IL-33 induced higher levels of Th2 and 
immunomodulatory cytokines such as IL-5, IL-10 and IL-13. 
Interestingly, as shown in Figure 3A, the combination of IL-33 and pbIgG 
induced higher levels of these cytokines, when compared to IL-33 single 
stimulation. 
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Figure 3. IL-33 skews mast cells toward an immunomodulatory phenotype.  
A, comparison between single and combined stimulations with IL-33 and pbIgG. B, 
Synergy, assessed as in Figure 1B. n=3 mast cell donors, 3 independent experiments, 
measured by multiplex (only the mediators significantly increased upon stimulation of 
mast cells with either IL-33 or pbIgG are shown). *p<0.05 determined by ANOVA with 
Bonferroni’s post-test (A) and by Student t test (B). Modified from Rivellese F, et al. 
Arthritis Rheumatol. 2015 Sep;67(9):2343-53. doi: 10.1002/art.39192. 
 
 
 
38 
 
On the contrary, no additional effects of IL-33 could be observed on top of 
IgG for the pro-inflammatory mediators such as TNF-or FLT-3Ligand. In 
line with the data presented in Figure 2B, the combined stimulation showed 
a synergistic effect that was only present for the mediators induced by IL-
33 (Figure 3B).  
Altogether, these data indicate that IL-33 is not simply enhancing mast cell 
activation by IgG, but is actually able to fine tune mast cell activation, 
inducing the production of a specific set of Th2-associated and 
immunomodulatory mediators. 
Interaction of mast cells with synovial immune cells  
To better understand the possible consequences of mast cell activation at 
the synovial level in RA, we investigated the occurrence of cellular 
interactions between mast cells and other immune cells ex vivo, by 
performing immunofluorescent stainings for mast cells tryptase together 
with the monocyte/macrophage marker CD14, the B cell marker CD19 or 
the T cell marker CD3 on tissue sections from synovia of RA patients. We 
found numerous tryptase+ cells (mast cells) scattered in the synovium of 
RA patients. Interestingly, tryptase+ cells showed clear cell-to-cell 
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interaction with CD14+ (Figure 4A), CD3+ (Figure 4B) and CD20+ cells 
(Figure 4C).  
 
Figure 4. Mast cells interaction with immune cells in RA synovium 
A-C, Immunofluorescence analysis of RA synovia, showing tryptase+ mast cells, in red, 
closely interacting with other immune cells, in green: CD14+ cells (A), CD3+ T cells 
(B) and CD20+ B cells (C). In blue nuclear staining (DAPI). Representative images 
from one donor out of three showing similar results. Modified from Rivellese F, et al. 
Arthritis Rheumatol. 2015 Sep;67(9):2343-53. doi: 10.1002/art.39192. 
 
To quantify these interactions, we counted the number of tryptase+ cells in 
close contact with each cell type. As shown in Table 1, a substantial 
proportion of mast cells (mean of 19.5 %) was found to be in contact with 
CD14+ cells in the synovia of RA patients. Similarly, the proportion of total 
CD14+ cells interacting with mast cells was considerably higher compared 
to B and T cells. 
40 
 
These results show that mast cells in the synovia of RA patients are in close 
contact with immune cells. In particular, a substantial number of synovial 
mast cells are localized in proximity of synovial CD14+ cells. 
Table 1. Interactions between mast cells (MCs) and other immune cells in RA synovia  
RA 1 RA 2 RA 3 Mean* 
Mast cells 31.3 11.7 30.7 24.6 
Close to CD14+ 6.7 (21.4%) 1.7 (14.6%) 6 (19.6%) 4.8 (19.5%) 
Mast cells 18.7 24 26.3 23 
Close to CD20+ 1.7 (9.1%) 3 (12.5%) 0.3 (1.1%) 1.7 (7.3%) 
Mast cells 27.3 25.6 38.3 30.4 
Close to CD3+  3.3 (12.1%) 1.7 (6.6%) 2 (5.2%) 2.3 (7.6%) 
     
CD14+ cells 80.7 7.0 125.3 71 
Close to mast cells 8.3 (10.3%) 0.3 (4.3%) 11.0 (8.8%) 6.5 (9.2%) 
CD20+ cells 49.6 45.0 240.3 111.6 
Close to mast cells 1 (2.0%) 0.3 (0.7%) 2.3 (1%) 1.2 (1.1%) 
CD3+ cells 358.6 0 14.7 124.4 
Close to mast cells 6.7 (1.9%) 0 (0 %) 0 (0 %) 2.2 (1.8%) 
Means of the number of cells counted in 10 high power fields by 3 independent and 
blind observers. RA = Rheumatoid arthritis. n=3. *Mean of the three patients.  
Modified from Rivellese F, et al. Arthritis Rheumatol. 2015 Sep;67(9):2343-53. doi: 
10.1002/art.39192. 
 
 
 
41 
 
 
Modulation of monocyte responses by mast cells 
Since a substantial proportion of mast cells were located near CD14+ cells 
in synovium (Figure 4 and Table 1), we next examined whether IL-33-
primed mast cell supernatants were able to influence the activation of 
CD14+ cells. To this end, LPS was used to boost the pro-inflammatory 
activation of CD14+ monocytes, as a model for TLR-4-induced activation 
of monocyte. Monocyte responses were evaluated in the presence or 
absence of mast cell supernatants. We used TNF-production as read-out 
because mast cells produce little amounts of TNF-compared to LPS-
stimulated monocytes. Figure 5A shows that the supernatants of mast cells 
inhibited the TLR4-mediated TNF- production by monocytes. The 
activation of mast cells with IL-33 and pbIgG significantly enhanced the 
inhibition of TNF- production without affecting monocyte survival 
(measured by DAPI staining, data not shown). This effect was in part 
dependent on IL-10, as it could be partially inhibited by IL-10 blocking 
antibodies (Figure 5B). In addition, blocking of histamine receptor 2 with 
ranitidine also partially reverted TNF- production by monocytes. When 
both histamine and IL-10 were blocked, the ability of monocytes to produce 
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TNF-was further retained. Importantly, direct effects of IL-33 on 
monocytes were excluded as no effect on the release of cytokines by 
monocytes was observed after adding this cytokine to the control media. 
Membrane markers of monocyte activation were also evaluated and the 
influence of mast cell mediators was assessed with blocking experiments. 
Interestingly, the LPS-induced expression of the co-stimulatory molecule 
CD80 was reduced by mast cell supernatants (Figure 5C), an effect mainly 
dependent on histamine, as it could be reverted by histamine receptor 2 
antagonist ranitidine. 
Altogether, these data indicate that IL-33 triggered mast cells inhibit the 
pro-inflammatory responses of monocytes, as shown by the suppression of 
TNF-production and CD80 expression, presumably through the release of 
IL-10 and histamine. 
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Figure 5. Mast cells modulate monocyte activation 
A, Monocytes were incubated with control media, containing the same stimuli used for 
mast cells (i.e. IL-33, white bars), or mast cell supernatants (black bars) and triggered 
with LPS. TNF- levels were measured by ELISA after 18h. TNF- levels in mast cell 
supernatants were below detection levels (dotted line). B, Monocytes were incubated 
with the supernatants of activated mast cells and anti-IL-10 blocking antibody, 
correspondent isotype control and histamine receptor 2 antagonist ranitidine. LPS-
induced TNF- is shown as percentage over control, with control media set as 100%. C, 
Flow cytometry analyses of the expression of CD80 by monocytes triggered with LPS 
after incubation with IL-33 + pbIgG mast cell supernatants, with IL-10 blocking and 
ranitidine. A-B, Data is shown as mean + SEM, n=6 monocyte donors and 12 mast cells 
donors, 5 independent experiments. C, Mean + SEM from n=6 monocyte donors and 8 
mast cell donors, 4 independent experiments, with histograms of a representative 
experiment on the right *p<0.05 For comparison between two groups, Student t test was 
performed. For multiple comparison of conditions, ANOVA was used with Bonferroni’s 
post-test. Modified from Rivellese F, et al. Arthritis Rheumatol. 2015 Sep;67(9):2343-
53. doi: 10.1002/art.39192. 
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Synovial expression of mast cell-related genes inversely associates with 
disease activity in early RA patients 
 To investigate whether the mast cell mediated 
immunomodulatory/homeostatic functions we observed in vitro might have 
a functional relevance in RA patients, we analysed the mRNA extracted 
from synovial biopsies of RA patients with early disease (<12 months), 
naïve to DMARDs therapy. As expected, the levels of mRNA of immune 
cells markers (e.g. CD3, CD14, CD16) and TNF- were significantly 
higher in patients with severe disease activity (i.e. DAS28 >5.2) than in 
patients with moderate disease activity (i.e. 3.2 >DAS28 ≤5.1) (Figure 6A). 
In contrast, the opposite observation was made for the mRNA-expression 
levels of mast cell-specific genes, selected on the basis of a recent study 
describing highly specific genes for human mast cells (39). Using the 
mRNA levels of these genes as a proxy for the presence of mast cells, we 
observed that most of the mast cell-related genes (such as, for example, c-
kit, tryptase  and chymase, etc.) displayed a significantly lower 
expression in patients with severe disease activity (i.e. DAS28 >5.2) than in 
patients with moderate disease activity (i.e. 3.2 >DAS28 ≤5.1) (Figure 6B). 
These data are in line with the observations made in our in vitro studies, as 
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they suggest that mast cell markers, unlike other immune cells, are not 
associated with a more severe clinical phenotype.  
Finally, the mRNA levels of IL-33 showed an inverse correlation with pro-
inflammatory markers, such as CD14, the FcRIIIa and TNF-Figure 6C).  
Together, these data further support our hypothesis that IL-33 triggered 
mast cells have an immunomodulatory/homeostatic role in RA and could 
potentially influence the disease severity in patients with RA.  
 
Figure 6. Gene expression in the synovia of early RA patients. 
A, mRNA levels of immune cell markers and TNF-in patients with moderate (3.2 > 
DAS-28 ≤ 5.1, empty dots) and severe (DAS-28 > 5.2, filled dots) disease activity. B, 
mRNA levels of mast cell-specific genes in patients grouped as above. C, Correlation of 
IL-33 mRNA levels with CD14, FcRIIa and TNF- Each dot represents a single 
patient, with line at the mean in A and B and regression line in C. n=40 *p<0.05 with 
Student t test performed to compare means of expression levels in two groups of patients 
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(moderate Vs severe DAS-28) for each gene in A and B and Pearson’s correlation in C. 
Modified from Rivellese F, et al. Arthritis Rheumatol. 2015 Sep;67(9):2343-53. doi: 
10.1002/art.39192. 
 
Synovial mast cells correlate with synovial inflammation and cellular 
infiltration in patient with early RA  
Having found that mast cell activation in synovia can be differently induced 
toward pro-inflammatory or immunomodulatory responses, we wondered if 
mast cells, as tunable effector cells, could have various functions in 
different patient subsets, and, possibly, in different disease stages, further 
adding complexity to the heterogeneity of RA. 
To address this question, we analysed the presence of mast cells in the 
synovia obtained by ultrasound-guided biopsy from a large cohort of 
patients (n=90) with early RA. Table 2 shows a summary of patient 
characteristics. Importantly, these patients had disease duration of less than 
12 months (early RA) and were naïve to therapy with DMARDs, allowing 
for the first time the study of synovial inflammation without the biases of 
long-standing disease and/or immunosuppressive therapy.  
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Table 2. Summary of patient characteristics (n=90) 
Age, years mean (SD), range 52 (16) 19-89 
Sex (% Female)  72.3%   
DAS-28 mean (SD), range 5.64 (1.39) 1.88-8.92 
ACPA+ % 78.7%   
RF+ % 74.5%  
ESR (mm/h) mean (SD), range 39 (30) 2-120 
CRP mean (SD), range 17 (27) 0-162 
Disease onset (Months) mean (SD), range 6 (3) 1-12 
 
As shown in Figure 7, MCs were positively correlated with the degree of 
synovial inflammation, evaluated by the Krenn score, a validated 
measurement taking into account the enlargement of lining cell layer, the 
cellular density of synovial stroma and the leukocytic infiltrate 51. 
MCs correlated with the infiltration of T cells, B cells, macrophages and 
plasma cells. Of particular interest is the strong correlation with B cells.  
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Figure 7. Mast cells correlate with synovial inflammation 
Density of mast cells (number of cells/mm2) in relation to synovitis score, and 
semiquantitative score of T cell, B cells, macrophage and plasma cells. n=90. Spearman 
correlation. 
 
We have then stratified patients according to MC numbers, as shown in 
figure 8 A.  
The results in table 3 indicate that the groups of patients with high mast cell 
counts have significantly higher levels of inflammatory markers (CRP and 
ESR) and a higher prevalence of antibody positivity (both RF and ACPA). 
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Table 3. Stratification of patients according to mast cell number 
  MAST CELLS 
STRATIFICATION 
 
 All  
(n=90, 
100%)
Low 
(n=29) 
Medium 
(n=29) 
High 
(n=31) 
P 
value* 
Female, %  72.3% 68.8% 71.9% 72.7% 0.985 
Age, mean (SD) 52 (16) 50 (15) 54 (17) 52 (15) 0.562 
ESR, mean (SD) 39 (30) 28 (28) 42 (30) 49 (29) 0.018 
CRP, mean (SD) 17 (27) 7 (15) 22 (33) 21 (25) 0.036 
RF+, % 74.5% 61.3% 65.6% 93.9% 0.002 
ACPA+, % 78.7% 74.2% 68.8% 93.5% 0.042 
DAS28, mean (SD) 5.64 (1.39) 5.16 (1.51) 
5.85 
(1.26) 5.91 (1.31) 0.059 
Krenn score, mean 
(SD) 4.56 (2.17) 3 (1.44) 
4.55 
(2.14) 5.77 (1.93) <0.001 
Pathotypes <0.001 
Fibroid, % 21.3% 51.6% 12.5% 0.0% 
Myeloid, % 29.8% 35.5% 37.5% 16.1% 
Lymphoid, % 48.9% 12.9% 50.0% 83.9% 
*one way Anova or Chi Square test 
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Additionally, the level of synovitis, measured by the Krenn score, was 
significantly different among the three groups, with higher scores in 
patients with high mast cell counts, in agreement with the previously shown 
correlations between mast cell numbers and the synovitis score. 
Finally, the proportion of lymphoid pathotype was significantly higher in 
patients with high vs intermediate vs low MC count (83.9% vs 50% vs 
12.9%, respectively, p<0.0001, table 3 and Figure 8 B). Similarly, synovial 
MCs were significantly higher in patients with a lymphoid pathotype (mean 
MC density in lymphoid 41.06/mm2 Vs fibroid/myeloid 11.66/mm2, 
p<0.0001, Figure 8 C).  
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Figure 8. Stratification of RA patients according to mast cell numbers and 
association with lymphoid pathotype 
A, Patients were stratified according to MC numbers as low MC count (<33rd 
percentile), Medium MC count (33rd-66th percentile) and high MC count (>66th 
percentile). The pictures on the right show how this stratification, although 
mathematical, corresponds to a clearly histological difference in the number of 
infiltrating mast cells. B, % of ELS positivity in patients stratified as in A. C, Density of 
mast cells in patients stratified according to the synovial pathotype. P<0.05, Chi Square 
in B and Mann Whitney in C.  
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Overall, these results indicate that MCs strongly associate with the 
lymphoid synovial pathotype in early RA patients. 
We then studied the cellular interaction at synovial level, using tonsils as a 
control of an organ with aggregates of B and T cells (i.e. the germinal 
centres of secondary lymphoid organs). Double immunofluorescence 
showed MCs bordering the germinal centres in secondary lymphoid organs. 
Similarly, mast cells were found in close contact with B and T cell 
aggregates in synovia of RA patients, which is confirming that mast cells 
have a spatial interaction with synovial B cell aggregates (Figure 9). 
 
 
 
 
 
 
 
Figure 9. Mast cells bordering lymphoid aggregates in tonsil (left) and RA synovia. 
Immunofluorescence analysis showing mast cells (in clear blue), T cells (in red) and B 
cells (in green) in tonsil germinal centres (left) and synovial lymphoid aggregates 
(right). 
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Synovial mast cells are functional associated to ectopic lymphoid 
structures 
Having found an association between the presence of mast cells and 
lymphoid pathotype, and a co-localization of mast cells and lymphoid 
aggregates in synovia, we wondered whether the interaction between mast 
cells and B cells has also functional consequences. 
To address this hypothesis, we co-cultured primary mast cells with naïve 
(IgD+) B cells isolated from tonsils. The preliminary results of these 
experiments suggest that mast cells are able to support B cell survival 
(Figure 10, A), proliferation (Figure 10, B) and differentiation (Figure 10, 
C). Interestingly, MCs induced a full differentiation of naïve B cells into 
antibody producing cells, as demonstrated by and the induction of IgG 
production upon co-culture of B cells with MCs (Figure 10, D). 
Importantly, the IgG class-switching was dependent on cell contact, as it 
was fully abrogated when cells were separated by a transwell membrane. 
As for the effect of mast cells on survival and proliferation, these were only 
partially abrogated by transwell, which is suggesting an additional 
contribution of soluble mediators.  Potential candidates are CD40L and IL-
6, both known to be expressed/produced by human mast cells, and 
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additional studies will be needed to unravel the mechanisms underlying the 
interaction between mast cell and B cells. 
Altogether, these data indicate that mast cells are able to support B cell 
survival, activation and differentiation, suggesting that they may contribute 
to functional activation of lymphoid aggregates in vivo.  
 
Figure 10 Mast cell and B cell coculture 
Naïve (IgD+) B cells isolated from tonsils were co-cultured with primary mast cells. 
Cells were in contact or separated by a transwell™ membrane. A, proportion of live B 
cells, in unstimulated cells (left) and cells stimulated with CPG (right). B, Proportion of 
naïve B cells, gated as CD20+IgDhiCD38-CD27-. C, Proportion of divided cells and 
division index (average number of cell divisions that a cell in the original population has 
undergone) calculated by CFSE incorportation. D, IgG measured by ELISA. One 
preliminary experiment in triplicate.  
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Synovial mast cells as predictors of radiographic progression 
Because our results suggest that high counts of synovial mast cell at 
baseline are associated with antibody positivity and a higher degree of local 
and system inflammation, and in particular is with lymphoid-rich 
inflammation, we hypothesized that the presence of mast cell could identify 
a subset of patients (a mast cell-rich pathotype) with specific clinical 
features. As already outlined in table 3, high numbers of mast cells at 
baseline was associated with higher inflammatory state and antibody 
positivity, which are typical feature of a severe disease. Accordingly, the 
number of mast cells showed a positive correlation with inflammatory 
parameters (ESR and CRP), with disease activity score (DAS28) and its 
components (tender and swollen joints) (Figure 11). 
 
 
 
 
 
 
Figure 11. Correlation of mast cell counts with markers of disease activity 
56 
 
This is suggesting that higher number of synovial mast cells is associated 
with a more severe clinical phenotype. As RA is a chronic disease with a 
great deal of heterogeneity in terms of progression and response to therapy, 
we wondered whether the different mast cell counts at baseline would help 
to predict the disease progression. The PEAC study was an observational 
study, in which patients were treated according to local guidelines, 
therefore starting standard therapy according to local and international 
guidelines with DMARDS and re-assessed at 6 months interval up to 2 
years. Most of the patients were treated with DMARD combinations, as 
specified in table 4. 
Table 4. Overview of therapy   
DMARDs number   
1 11.80%  
2 81.20%  
3 7.10%  
   
DMARDs combinations  
MTX 3.5%  
HCQ 5.9%  
SSZ 2.4%  
MTX+SSZ 64.7%  
MTX+HCQ 15.3%  
SSZ+HCQ 1.2%  
MTZ+ASA+HCQ 7.10%  
MTX=methotrexate; HCQ=hydroxychloroquine; SSZ=sulfasalazine 
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Preliminary results from the analysis of the 12m follow-up, shown in table 
5, indicate that the baseline presence of mast cells is not associated with 
differences in inflammatory markers or disease activity at 12 months or 
with response to therapy, evaluated according to the EULAR criteria 58, or 
remission rates, defined as a DAS-28 score <2.6.  
**one way Anova or Chi Square test. 
 
 
Table 5. Stratification of patients according to MC counts and 12m follow-up 
   Baseline MAST CELL 
STRATIFICATION 
  
12m follow-up 
All  Low Medium High P 
value*(n=70, 100%) (n=25) (n=24) (n=24) 
ESR  21 14 17 17 0.078 
CRP 4 5 7 7 0.216 
DAS28 3.73 3.64 3.51 4.19 0.534 
EULAR response   0.277 
no response 30.6% 42.1% 22.7% 28.9%   
moderate response 25.8% 21.1% 18.2% 38.1%   
good response 43.5% 36.8% 59.1% 33.3%   
DAS28<2.6 37.1% 31.6% 45.5% 33.3% 0.569 
Radiographic progression 16.4% 4.0% 12.5% 33.3% 0.018 
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Interestingly, the proportion of patients showing radiographic progression 
at 1yr (defined as an increase in the Van der Heijde-modified Sharp score 
by more than 1 point over 1 year), was significantly higher in patients with 
high Vs medium and low mast cell counts.  
These results suggest that high mast cell counts at baseline are associated 
with a higher risk of radiographic progression, as shown in Figure 12 A and 
further confirmed by the analysis in Table 6, showing that the high MC 
counts (>66th percentile) confer a 12-fold higher risk of RP compared to 
low MC counts (<33rd percentile). 
Table 6. Mast cell stratification and odds ratio of radiographic progression  
Radiographic 
progression  
Tot
al 
no yes 
Mast cell stratification  <33rd percentile 24 1 25 
>66th percentile  16 8 24 
Total 40 9 49 
Odds Ratio High Vs Low MC count 
(95% CI) 
12 (1.366 - 
105.411) 
 
This observation suggests that the presence of mast cells in synovia could 
be used to identify a subgroup of patients with a high risk of radiographic 
progression. 
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However, it could be easily objected that mast cells in this context are 
simply markers of inflammation, as we have previously shown that higher 
numbers of mast cells are associated with local and systemic inflammation 
and, more specifically, with lymphoid infiltration. Accordingly, the data in 
figure 11 B confirms that the lymphoid pathotype is also associated with a 
higher rate of radiographic progression, which would indicate that the 
association of mast cells with radiographic progression is indirect. 
However, as shown in figure 11 C, if patients with lymphoid pathotype are 
selected, only those with high mast cell counts show high rates of 
radiographic progression, indicating that mast cell association with 
radiographic progression is independent from the pathotype.  
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Figure 12. Mast cell counts, pathotypes and radiographic progression.  
To identify additional factors potentially associated with radiographic 
progression, we compared various baseline clinical parameters at baseline 
in the two groups (radiographic progressors Vs non-progressors). The 
results of this analysis (not shown), identified the following factors to be 
significantly different in the two groups: mast cell counts, Krenn score, age 
at inclusion, presence of ELS and baseline Sharp score. There was no 
difference in baseline disease activity (DAS-28), inflammatory markers 
(CRP, ESR) or antibody positivity, which is somehow surprisingly but in 
line with previous reports showing that single markers, including 
inflammatory markers, are not always able to predict radiographic 
61 
 
progression59. To assess the individual contribution of mast cells to the 
prediction of radiographic progression, we performed a logistic regression 
analysis entering the mentioned baseline variables (age, Krenn score, mast 
cell counts, synovial pathotypes and baseline Sharp score). Performing a 
backward stepwise regression we found that the best fit, predicting erosions 
correctly in 86.6% of cases (Nagelkerke R Square of 0.241), could be 
obtained with a model including mast cell counts (high MC count Vs 
medium/low MC count), age and baseline Sharp Score (table 7), with mast 
cells giving the main contribution (p=0.019) to the prediction of 
radiographic progression. Interestingly, this analysis confirmed that high 
MC counts confer a significantly higher risk of radiographic progression 
compared to medium/low MC count (OR 5.7, CI 1.338-24.296). Altogether, 
these results indicate that mast cells, in addition to being a simple marker of 
synovial inflammation, could help identifying a specific subset of patients 
with a higher risk of radiographic progression.  
Table 7. Logistic regression analysis of radiographic progression (best fit) 
p Odds ratio 
95% C.I. 
Lower Upper 
Baseline Sharp Score  .743 .978 .857 1.117 
Age .062 1.049 .998 1.103 
MC High VS low/medium  .019 5.702 1.338 24.296 
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CONCLUSIONS 
Mast cells, as part of the inflammatory infiltrate in the synovia of RA 
patients, exert complex and sometimes controversial effects in the 
pathogenesis of RA. 
In fact, several lines of evidence indicated that mast cell activation can 
contribute to the unbalanced inflammatory response in the course of RA. 
Accordingly, we have shown here that mast cells can be activated by 
immune-complexes formed by ACPA from the sera of RA patients bound 
to citrullinated antigens, a response that can be augmented by Toll-like 
receptors triggering.  
At the same time, we have also identified IL-33-mediated mast cell 
activation as a new mechanism able to down-regulate immune responses 
upon specific triggering in the context of RA. In fact, we found that IL-33 
induces human mast cells to release immunomodulatory mediators, such as 
IL-10 and histamine, as well as other cytokines associated with type 2 
immune responses such as IL-5 and IL-13. The release of these IL-33-
induced mediators was further enhanced by IgG triggering. In particular, 
the combined stimulation with IL-33 and IgG showed a synergistic effect 
that, intriguingly, was present for IL-33-induced mediators (such as IL-5, 
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IL-10, IL-13 and histamine) and absent for mediators induced by IgG (such 
as CXCL8/IL-8). These data are important as they indicate that IL-33 is 
able to prime mast cell toward a Th2/immunomodulatory phenotype, a 
phenotype that becomes more prominent upon concomitant activation of 
mast cells by IgG. 
Having found such tunable responses by mast cells, we explored their 
ability to influence the response of other synovial immune cells. Mast cells 
triggered with IL-33 and pbIgG were able to dampen monocyte activation, 
inhibiting the production of the prototypical pro-inflammatory cytokine 
TNF- and the upregulation of the co-stimulatory molecule CD80. These 
effects were mediated, at least in part, by the release of IL-10 and histamine 
from mast cells.  
These results indicate that mast cells, in addition to their well-known pro-
inflammatory functions, are also able to mediate regulatory/homeostatic 
responses, in particular when exposed to IL-33.  
To confirm the relevance of the latter hypothesis, we studied a cohort of 
early (<12 months) RA patients naïve to DMARD therapy. Interestingly, 
while the presence of many types of immune cells, as determined by cell-
specific gene-expression, was associated with high disease activity, the 
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presence of mast cells displayed an inverse association with disease 
severity. At the same time, IL-33 was inversely correlated with pro-
inflammatory markers, such as CD14, CD16 (FcRIIIA) and TNF-. 
Overall, these data suggest that mast cells can exert both pro- and anti-
inflammatory effect, with the net result depending on a fine balance of 
different triggers. As a consequence, we hypothesised that mast cell 
contribution to RA could vary in different disease stages and, considering 
the well-known heterogeneity of RA, they could play different roles in 
different disease subsets.  
To explore this hypothesis, overcoming the discussed limitation of animal 
models that do not take into account the disease heterogeneity and only 
study one aspect of the disease process, we directly evaluated the presence 
of mast cells in synovial tissue obtained by ultrasound-guided synovial 
biopsies. The analysis of a large cohort of patients (n=90) with early RA, 
naïve the DMARD therapy, indicated that high mast cell numbers are 
associated with antibody positivity, with local and systemic inflammation 
and with the degree of cellular infiltration. In particular, higher numbers of 
mast cells strongly associate with a lymphoid pathotype. The ability of mast 
cells to support B cell survival, activation and differentiation in vitro 
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suggests that they may contribute to functional activation of lymphoid 
aggregates in vivo, warranting additional studies to establish the role of MC 
interaction with B cells.  
In addition to the implications of these results toward a better understanding 
of RA pathogenesis, our study also show that synovial mast cell emerge as 
potential markers for patient stratification. In fact, our preliminary analysis 
of the 12 months follow-up indicates that the presence of mast cells at 
baseline represents an independent predictor of radiographic progression at 
one year. This was independent from the association of mast cells with 
baseline disease activity and inflammatory markers. Additionally, the 
association of mast cells with radiographic progression was independent 
from local inflammation, including the presence of lymphoid-rich 
inflammatory infiltrate. This observation is of utmost importance, as joint 
damage is one of the central aspects of rapid progressive disease, and 
radiographic progression is difficult to predict 60. For example, high disease 
activity is considered a negative prognostic factor for radiographic 
progression, but the exact correlation between inflammatory markers, 
disease activity and radiographic progression is still being debated59. Our 
results indicate that mast cells are predictors of radiographic progression, 
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independently from their association with baseline inflammatory markers or 
disease activity. In other words, within the group of patients with high 
disease activity, the presence of high numbers of mast cells seem to be 
specifically associated with radiographic progression. This observation has 
biological plausibility, as mast cell release several mediators able to induce 
bone erosions. Accordingly, patients with mastocytosis, a clonal disorder of 
mast cells, have a deranged bone metabolism with high incidence of 
osteoporosis and bone fractures61. We have also found (preliminary data, 
not shown) that primary mast cells express RANKL, the most important 
factor in the regulation of bone metabolism, also involved in bone 
destruction in RA 62.  However, the exact role of mast cells in the regulation 
of bone metabolism is unknown and further studies will be needed to 
unravel the contribution of mast cells to bone erosions in the context of RA. 
Our observations suggest that the presence of mast cells in synovia could 
help identifying a subgroup of patients with a high risk of radiographic 
progression, in which a more aggressive treatment plan should be 
considered, ideally aimed at preventing bone erosions. In fact, patients 
stratified according to baseline MC counts did not show any difference at 
the 12m follow-up in terms of inflammatory markers, disease activity and, 
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most importantly, response to treatment (table 5). This is particularly 
interesting considering the recent observation that therapies, mainly with 
biologicals63, but possibly also with standard DMARDs 64, may disconnect 
the relationship between disease activity and joint damage. Accordingly, 
patients with high baseline MC counts showed significantly higher rates of 
radiographic progression, which is “disconnected” from the inflammatory 
markers and disease activity, as these show a similar decrease in all patients 
at 12 months, independently from their stratification according to mast cell 
counts. In other words, high mast cell counts seem to identify a group of 
patients with an aggressive disease. These patients seem to have an 
apparently good response to therapy, with reduction of inflammatory 
markers and disease activity score. Nonetheless, in these patients the 
disease is still active, as they show radiographic progression. Considering 
that bone damage is the most dreadful consequence of RA, leading to 
severe disability in the long term, it is clear how these patients would 
require a more aggressive therapy, ideally aimed at preventing bone 
erosions, possibly by specifically targeting mast cells.   
Our future plans include assessing whether mast cell numbers correlate 
with response to biological DMARDs, to understand whether mast cells can 
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further dissect the heterogeneity of RA, allowing the stratification of 
patients to the right treatment, toward the goal of personalized medicine 65. 
Overall, the data presented in this dissertation indicate that mast cells give 
an important but multifaceted and sometimes controversial contribution to 
the pathogenesis of RA. The direct analysis of mast cells in the synovia of 
RA patients is a promising tool to help dissecting the histopathological and 
clinical heterogeneity of RA. In particular, our data suggest that their 
presence, independently from local and systemic inflammatory markers and 
disease activity scores, help identifying a group of patients with high risk of 
radiographic progression. Additional studies are warranted to better clarify 
mast cell involvement in the pathogenesis of RA and, from the clinical 
point of view, assess whether their presence in synovia can help to stratify 
patients to the most-effective treatment. 
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